Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphadenopathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    351 result(s) found for: Lymphadenopathy. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-001356-10 Sponsor Protocol Number: Revail Start Date*: 2012-01-12
    Sponsor Name:LYSARC
    Full Title: STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA ...
    Medical condition: Angioimmunoblastic T-cell Lymphoma (AITL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003526-80 Sponsor Protocol Number: CLSG-PTCL-CHEPA Start Date*: 2021-12-16
    Sponsor Name:Kooperativní lymfomová skupina, z.s.
    Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas.
    Medical condition: Peripheral T-cell lymphomas (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002450 Angioimmunoblastic T-cell lymphomas HLT
    20.0 100000004851 10001414 Adult T-cell lymphomas/leukaemias HLT
    20.0 100000004851 10022704 Intestinal T-cell lymphomas HLT
    20.0 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    21.0 100000004864 10002451 Angioimmunoblastic T-cell lymphoma NOS LLT
    21.0 100000004864 10001415 Adult T-cell lymphoma/leukaemia NOS LLT
    21.1 100000004864 10076434 Hepatosplenic gamma-delta T-cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003969-33 Sponsor Protocol Number: IPH4102-201 Start Date*: 2019-07-19
    Sponsor Name:Innate Pharma SA
    Full Title: TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in p...
    Medical condition: Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF). AngioImm...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002450 Angioimmunoblastic T-cell lymphomas HLT
    20.0 100000004851 10002235 Anaplastic large cell lymphomas T- and-cell types HLT
    20.0 100000004851 10028484 Mycoses fungoides HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) ES (Temporarily Halted) IT (Ongoing) BE (Trial now transitioned) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023040-32 Sponsor Protocol Number: ROMI-ADVM-004 Start Date*: 2011-05-05
    Sponsor Name:Celgene Corporation
    Full Title: A phase IV, Open-Label, Single-Arm ROLLOVER STUDY FOR SUBJECTS WHO PARTICIPATED IN OTHER ROMIDEPSIN PROTOCOLS. Estudio de extensión de fase IV, abierto, de un solo brazo para pacientes que hayan p...
    Medical condition: Rollover study supporting all indications from prior Romidepsin protocols eligible for participation in this study. Estudio de extensión que recoge todas las indicaciones de protocolos anteriores d...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001414 Adult T-cell lymphomas/leukaemias HLT
    12.1 10042971 T-cell lymphoma LLT
    12.1 10042979 T-cell lymphoma recurrent LLT
    12.1 10042980 T-cell lymphoma refractory LLT
    12.1 10042981 T-cell lymphoma stage I LLT
    12.1 10042982 T-cell lymphoma stage II LLT
    12.1 10042983 T-cell lymphoma stage III LLT
    12.1 10042984 T-cell lymphoma stage IV LLT
    12.1 10002450 Angioimmunoblastic T-cell lymphomas HLT
    12.1 10022704 Intestinal T-cell lymphomas HLT
    12.1 10034622 Peripheral T-cell lymphomas NEC HLT
    12.1 10042988 T-cell unclassifiable lymphomas HLT
    12.1 10001414 Adult T-cell lymphomas/leukaemias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003982-17 Sponsor Protocol Number: SGN35-015 Start Date*: 2020-10-21
    Sponsor Name:SEATTLE GENETICS, INC.
    Full Title: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant...
    Medical condition: • Hodgkin lymphoma (HL) • CD30-expressing peripheral T-cell lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003983-28 Sponsor Protocol Number: SGN35-028 Start Date*: 2020-11-27
    Sponsor Name:SEAGEN INC.
    Full Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma...
    Medical condition: - classic Hodgkin lymphoma (cHL) - Systemic anaplastic large cell lymphoma (sALCL) - CD30-expressing peripheral T cell lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000468-41 Sponsor Protocol Number: CCDZ173X2201E1 Start Date*: 2016-07-19
    Sponsor Name:Pharming Technologies B.V.
    Full Title: An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinos...
    Medical condition: APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) NL (Ongoing) IE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003876-22 Sponsor Protocol Number: CCDZ173X2201 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CD...
    Medical condition: APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) NL (Completed) IE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005778-34 Sponsor Protocol Number: Zevalin first line in FL Start Date*: 2007-05-09
    Sponsor Name:Charité-Universitätsmedizin Berlin, Germany
    Full Title: Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolida...
    Medical condition: Patients with follicular lymphoma grade I-IIIa and stage III–IV (as well as for selected patients with extended abdominal stage II).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052314 Lymphatic disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Ongoing) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001624-14 Sponsor Protocol Number: LE3301 Start Date*: Information not available in EudraCT
    Sponsor Name:Pharming Technologies B.V.
    Full Title: An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kina...
    Medical condition: Activated Phosphoinositide 3-Kinase Delta Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10078281 Activated PI3 kinase delta syndrome PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004932-19 Sponsor Protocol Number: OMB110911 Start Date*: 2009-01-27
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    17.0 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    17.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    17.0 10005329 - Blood and lymphatic system disorders 10024295 Leukaemias chronic lymphocytic HLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008959 Chronic lymphocytic leukaemia (in remission) PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) SE (Completed) BE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004454-17 Sponsor Protocol Number: ACE-CL-309 Start Date*: 2016-10-24
    Sponsor Name:Acerta Pharma BV
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Rela...
    Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008978 Chronic lymphocytic leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Ongoing) SK (Completed) SE (Completed) ES (Ongoing) AT (Completed) DE (Completed) FR (Completed) BG (Completed) PL (Ongoing) HR (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001569-33 Sponsor Protocol Number: LLC-R-FCM-1 Start Date*: 2005-09-23
    Sponsor Name:Dept. Hematology, Hospital Clinic
    Full Title: First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamie...
    Medical condition: Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008556-16 Sponsor Protocol Number: PRADA Start Date*: 2009-07-13
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Pharmacokinetic and safety study of RAltegravir and atazanavir in a once DAily dose regimen in HIV-1 in-fected patients (PRADA)
    Medical condition: HIV infected patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000390-59 Sponsor Protocol Number: P03802 Start Date*: 2004-07-15
    Sponsor Name:SCHERING-PLOUGH
    Full Title: Safety and efficacy of SCH 417690 in HIV-infected treatment-naive subjects
    Medical condition: HIV-1 infected naive subject
    Disease: Version SOC Term Classification Code Term Level
    6.1 10020161 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004824-19 Sponsor Protocol Number: ML21206 Start Date*: 2008-08-08
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study
    Medical condition: Chronic Lymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003463-31 Sponsor Protocol Number: P04999 Start Date*: 2010-08-23
    Sponsor Name:Schering-Plough Research Institute
    Full Title: COVER- Registro de observación continua tras exposición Vicriviroc (VCV)
    Medical condition: Síndrome de inmunodeficiencia adquirida (SIDA)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    9.1 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006292-20 Sponsor Protocol Number: GS-US-312-0115 Start Date*: 2012-07-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chroni...
    Medical condition: Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) IT (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005758-36 Sponsor Protocol Number: UTX-TGR-304 Start Date*: 2016-10-28
    Sponsor Name:TG Therapeutics
    Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005405-21 Sponsor Protocol Number: UMCN-AKF 07.06 Start Date*: 2008-01-21
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: The influence of Raltegravir (MK_0518) on the pharmacokinetics of single-dose Lamotrigine in healthy male subjects (GRANOLA)
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 06 07:31:56 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA